For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | - | - | - | 0 |
| General and administrative costs | 1,654,031 | 1,772,400 | 1,750,658 | 714,161 |
| Research and development costs | 333,376 | 52,118 | 50,696 | 60,648 |
| Total costs and expenses | 1,987,407 | 1,824,518 | 1,801,354 | 774,809 |
| Loss from operations | -1,987,407 | -1,824,518 | -1,801,354 | -774,809 |
| Interest income | 3,370 | 2,152 | 4,430 | 365 |
| Interest expense | 3,096 | 3,756 | 457 | 1,810 |
| Unrealized gain (loss) on digital assets | - | - | -182,887 | - |
| Realized loss on digital assets | - | 568,521* | - | - |
| Foreign currency gain (loss) | -475 | 915* | -130 | - |
| Other income | - | 935* | - | - |
| Foreign currency gain | - | - | - | 581 |
| Net loss | -1,987,608 | -2,392,793* | - | - |
| Net loss attributable to common stockholders | - | -2,612,967 | -1,980,398 | -775,673 |
| Series b convertible preferred stock 8 cumulative dividend | -17,882 | 220,174* | -50,367 | - |
| Non-controlling interest | -63,932 | - | - | - |
| Net loss attributable to common stockholders | -1,941,558 | - | -2,030,765 | - |
| Basic EPS | -0.18 | - | -0.33 | -0.29 |
| Diluted EPS | -0.18 | -0.529 | -0.33 | -0.29 |
| Basic Average Shares | 10,889,003 | - | 6,171,195 | 2,720,533 |
| Diluted Average Shares | 10,889,003 | 4,840,731* | 6,171,195 | 2,720,533 |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)